Profile  Mission  Sitemap  Feedback  Events  ISO  Disclaimer  Policies

Corporate Office

Plant

IMS


   Products  

Terbin
Tablets

Composition: Properties: Pharmcokinetics:
Indication: Dosage and Administration: Tablets:
Skin infection: Hair and scalp infection: Onychomycosis:
Cream Likely duration of treatment: Use of Terbin® in elderly
Use of Terbin® in Children Contraindications: Warning and Precautions:
Interactions: Side Effects: Overdosage:
Available as:

Composition:
Each tablet contains Terbinafine 125mg (as hydrochloride).

Properties:
Terbinafine is an allylamine, which has a broad spectrum of anti-fungal activity. Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation squalene resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in fungal cell membrane. The enzyme squalene epoxidase is not linked to the cytochrome P450 system. The drug has rapid onset of action and can be effective with short treatment duration. At low concentration terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity against yeast is fungicidal or fungistatic, depending on the species.

Pharmcokinetics:
A single oral dose of 250mg terbinafine (2 tablets) results in peak plasma concentration of 0.97 µg/ml within 2 hours of administration. The absorption half-life is 0.8 hours and the distribution half-life is 4.6 hours. The bio-availability of terbinafine is moderately affected by food, but not sufficiently to require dosing adjustment. Terbin® tablet binds strongly to plasma protein (99%). It rapidly diffuses through the dermis and concentrates in the lipophillic stratum corneum. Terbinafine is also secreted in sebum, thus achieving high concentration in hair follicles, hair and sebum-rich skin and nails. Terbin® tablet is distributed into the nail plate in the first few weeks after commencing therapy. Bio-transformation results in metabolites with no anti-fungal activity, which are excreted predominantly in the urine. The terminal elimination half-life is 17 hours. There is no evidence of accumulation. No age-dependant changes in steady state plasma concentration, but the elimination rate may be reduced in patients with renal failure or hepatic impairment resulting in higher blood levels of terbinafine.

Indication:
Terbin®tablets is indicated for the treatment of: Fungal infection of skin, hair, nails caused by dermatophytes such as Trichophyton (e.g. T rubrum, T. mentagrophytes, T. verrucosum, T. tonsurans, and T. violaceum) Microsporum canis and Epidermophyton floccosum. Ringworms (tinea corporis, tinea cruris, tinea pedis and tinea capitis) Yeast infection of the skin caused by genus candida (e.g. Candida albicans) Onychomycosis (fungal infection of nails) caused by dermatophyte fungi.

Dosage and Administration:

Tablets:

Skin infection:

Hair and scalp infection:

Onychomycosis:

Cream

Likely duration of treatment:

Use of Terbin® in elderly

Use of Terbin® in Children

Contraindications:

Warning and Precautions:

Interactions:

Side Effects:

Overdosage:

Available as:

©   Copyrights 2005-2006 by Martin Dow Pharmaceuticals. All rights reserved.